Company / Operating Cash Flow
aTYR PHARMA INC Operating Cash Flow History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$62.0M
FY2025
5-year range
-$69.1M / -$15.3M
FY2021-FY2025
Trend
+10.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow returned to growth in FY2025 after 2 years of decline, reaching -$62M.
Based on SEC 10-K filings.
-$62M in FY2025.
Declined from -$33M to -$62M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow increased 10.3% year-over-year.
- Peak operating cash flow was recorded in FY2022.
- Lowest operating cash flow in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -6.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$62.0M | +10.3% |
| FY2024 | -$69.1M | -109.0% |
| FY2023 | -$33.1M | -116.2% |
| FY2022 | -$15.3M | +23.5% |
| FY2021 | -$20.0M | +35.6% |
| FY2020 | -$31.1M | +26.7% |
| FY2019 | -$42.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026